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Purpose: Postoperative ileus (POI) is an impairment of coordinated gastrointesti-
nal (GI) motility that develops as a consequence of abdominal surgery and is a ma-
jor factor contributing to patient morbidity and prolonged hospitalization. The aim 
of this study was to investigate the effects of different 5-hydroxytryptamine 4 (5-
HT4) receptor agonists, which stimulate excitatory pathways, on a POI model. 
Materials and Methods: The experimental model of POI in guinea pigs was creat-
ed by laparotomy, gentle manipulation of the cecum for 60 seconds, and closure 
by suture, all under anesthesia. Different degrees of restoration of GI transit were 
measured by the migration of charcoal. Colonic transit was indirectly assessed via 
measurement of fecal pellet output every hour for 5 hours after administration of 
various doses of mosapride, tegaserod, prucalopride, and 5-HT. Results: Charcoal 
transit assay showed that various 5-HT4 receptor agonists can accelerate delayed 
upper GI transit in a dose-dependent manner. However, fecal pellet output assay 
suggested that only prucalopride had a significant effect in accelerating colonic 
motility in POI. Conclusion: Although mosapride, tegaserod, and prucalopride 
produce beneficial effects to hasten upper GI transit in the POI model, prucalo-
pride administered orally restores lower GI transit as well as upper GI transit after 
operation in a conscious guinea pig. This drug may serve as a useful candidate for 
examination in a clinical trial for POI.
Key Words:   Postoperative ileus, 5-HT4 receptor agonist, gastrointestinal transit, 
prucalopride
INTRODUCTION
Postoperative ileus (POI) is the transient impairment of gastrointestinal (GI) motil-
ity that develops as a consequence of almost every abdominal surgical procedure 
and usually lasts 2-4 days for a conventional abdominal procedure but decreases to 
as little as ≤2 days in the case of laparoscopic surgery.1 Uncomplicated POI is gen-
erally recognized as a physiological response of the intestine to a traumatic event 
and thus can be disregarded. However, if POI is prolonged and left untreated, it 
may require nasogastric intubation and sometimes even parenteral nutrition. In ad-
dition, evidence continues to accumulate indicating that POI is accompanied by a 
significant increase in patient morbidity and by substantial hospitalization costs. A 
drug that could prevent or treat POI and shorten a patient’s hospital stay may lead 
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MATERIALS AND METHODS
　　　
Preparation of animals
Adult male Hartley guinea pigs (250-350 g, Charles River 
Laboratories, Inc., Wilmington, MA, USA) were acclimat-
ed to their holding room (temperature controlled at 21±1°C, 
50±10% humidity, and 12 h light/dark cycle commencing 
at 7:00 AM) for at least 1 week prior to surgery. A standard 
guinea pig diet and drinking water were provided ad libi-
tum. All experiments were conducted in accordance with 
the Guide for the Care and Use of Laboratory Animals pro-
vided by the Animal Laboratory Ethics Committees of the 
Department of Laboratory Animal Medicine, Medical Re-
search Center, Yonsei University College of Medicine.
Experimental design
Guinea pigs were subjected to a 24-hour fast with free ac-
cess to water before being anesthetized by intraperitoneal 
injection with pentobarbital sodium. The guinea pigs were 
randomly divided into three groups. In the first group, no 
incision or laparotomy was made under anesthesia (‘anes-
thesia’ group). The second group had a laparotomy that 
consisted of an incision through the abdominal skin, ab-
dominal muscle layers, and peritoneum and closure by su-
ture after the abdomen had been shaved and disinfected 
with 70% alcohol (‘sham operation’ group). The third group 
had a laparotomy followed by evisceration and gentle ma-
nipulation of the cecum using wet gauze for 60 seconds and 
was then closed by suture (‘POI’ group). After the group-
specific treatments, guinea pigs received vehicle, mosapride, 
tegaserod, prucalopride, or 5-HT through an orogastric can-
nula. All experiments were performed in the morning be-
tween 8:00 AM and noon.
Experimental design 1: upper GI transit
In the first series of experiments, the effects of various pro-
kinetic agents were tested via charcoal transit assay. The 
charcoal mixture consisted of charcoal, barium, and normal 
saline mixed in the ratio of 1 : 2 : 6. After the operations, 
the guinea pigs received an intragastric administration of 
charcoal mixture combined with vehicle (0.9% normal sa-
line, 1, 5, 10 mg kg-1, p.o.), mosapride (1, 5, 10 mg kg-1, p.o.), 
tegaserod (1, 5, 10 mg kg-1, p.o.), prucalopride (0.5, 1, 5, 10 
mg kg-1, p.o.), or 5-HT (1, 5, 10 mg kg-1, p.o.) through an 
orogastric cannula. Doses were selected based upon the re-
sults of our preliminary experiments as well as published 
to a significant reduction in healthcare costs and, more im-
portantly, will allow patients to leave the hospital earlier, 
lessen the possibility of acquiring serious hospital-based in-
fections, and promote faster recovery from abdominal sur-
gery.2
It has been reported that impairment of GI motility in-
duced by surgery is a result of multiple causes, including 
neural, inflammatory, and pharmacological mechanisms.3 
Of these mechanisms, it is the neural pathways that are 
mainly activated in the acute postoperative phase. Neural 
pathways are complicated, and are influenced by the num-
ber of factors including intensity of the stimulus. Briefly, 
incision of the skin and laparotomy activate the adrenergic 
inhibitory pathway, while gastrointestinal surgery involv-
ing handling of the bowel stimulates supra-spinal pathways 
that activate the hypothalamic-pituitary-adrenal stress axis 
and release corticotrophin-releasing factor. Moreover, GI 
motility may be inhibited by non-adrenergic, non-choliner-
gic (NANC) pathways. Multiple inhibitory NANC neu-
rotransmitters (e.g. nitric oxide, calcitonin gene-related pep-
tide, vasoactive intestinal polypeptide) located in the enteric 
nervous systems may also play an important role in the 
pathogenesis of POI.2,4 Herein, the authors hypothesized 
that stimulation of excitatory pathways could overcome the 
inhibitory neural pathways and ultimately prevent or im-
prove POI.
The 5-hydroxytryptamine 4 (5-HT4) receptor is an im-
portant drug target for medications intended to stimulate 
GI motility. Medications that act as agonists at this recep-
tor have been shown to have therapeutic potential in the 
treatment of GI motility disorders. Unfortunately, older 
5-HT4 receptor agonists were less selective and less specif-
ic, which caused them to have potential adverse cardiac ef-
fects or reduced intestinal prokinetic activity due to interac-
tions with other 5-HT receptors (e.g., antagonism at the 
5-HT3 receptor, as seen with cisapride). Additionally, the 
prokinetic agents which have effects mainly in the upper GI 
tract have not been proven effective in treating POI, likely 
because of their limited efficacy and inability to reverse the 
delay in large bowel transit following abdominal surgery. 
Despite the development of newer 5-HT4 receptor agonists, 
only limited data comparing the efficacies of the newer 
drugs to those of the previously existing 5-HT4 receptor ag-
onists has been reported. Herein, we evaluated the effects 
of 5-HT and various 5-HT4 receptor agonists including mo-
sapride, tegaserod, and prucalopride on a guinea pig model 
of POI.
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Belgium), and 5-HT (Sigma, Buchs, Switzerland, EU). 
These chemicals were freshly made for each experiment by 
dissolving each compound in isotonic sodium chloride so-
lution. 
Data analysis
The results of the upper GI transit experiment described the 
distance migrated by charcoal (cm) as a percentage (%) of 
the total length of the small intestine (cm). The measure-
ments of charcoal migration were made from the pylorus to 
the most distal point of migration of charcoal mixture, and 
the total length of the small intestine was evaluated from the 
pylorus to the end of the ileum at the time point 3 hours after 
administration of vehicle or drug. The results of the lower 
GI transit experiment are reported as the cumulative fecal 
pellet output including weight (g) and number at each of 
time point during the 5 hours after administration of vehicle 
or drug. For the charcoal transit assay, statistical significance 
was evaluated among the ‘anesthesia’, ‘sham operation’, 
and ‘POI’ groups using one-way ANOVA followed by a 
post-hoc Bonferroni test. For charcoal transit and fecal pellet 
output assays in the ‘POI’ group, statistical significance was 
assessed between the vehicle and each drug treatment by 
two-way ANOVA followed by the post-hoc Bonferroni test. 
To determine if the effects of drug treatment alone on char-
coal transit and fecal pellet output were dose-dependent, 
‘within group’ comparisons were made for the various doses 
at the same time-point using one-way ANOVA and the post-
hoc Bonferroni test. In all tests, statistical significance was 
assigned at p<0.05, based on the means from collected data. 
All data were analyzed using SPSS version 18.0 for Win-
dows software (SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Upper and lower GI transits in the POI model
The migration length of charcoal as a percentage (%) of the 
data.5 After 3 hours, the guinea pigs were sacrificed in the 
CO2 room. Upper GI transit was evaluated using the migra-
tion of charcoal mixture from the pylorus to the most distal 
point of migration, and charcoal migration was expressed 
as a percentage (%) of the total length of the small intestine 
(cm). The upper GI transit experiment was performed 3 
hours after surgery, based on the results of our preliminary 
experiments based on simple abdominal X-rays (Fig. 1).
Experimental design 2: lower GI transit
In the second series of experiments, we tested the effects of 
various prokinetic agents using a fecal pellet output assay. 
We did not perform the fecal pellet output assay with the 
‘sham operation’ group because there was no difference in 
upper GI transit between the ‘sham operation’ and ‘anesthe-
sia’ groups in our preliminary data. Fecal pellet output was 
measured in non-fasted guinea pigs receiving an intragas-
tric administration of vehicle (0.9% normal saline, 1, 5, 10 
mg kg-1, p.o.), mosapride (1, 5, 10 mg kg-1, p.o.), tegaserod 
(1, 5, 10 mg kg-1, p.o.), prucalopride (0.5, 1, 5, 10 mg kg-1, 
p.o.), or 5-HT (1, 5, 10 mg kg-1, p.o.) through an orogastric 
cannula 1.5 hours after the anesthesia with or without oper-
ation. Each guinea pig was placed into an individual experi-
mental cage, and both weight and number of fecal pellets 
produced were measured and recorded in 1-hour incre-
ments for the first 4 hours and in 30-minute increments for 
the last 1 hour. As a result, a 5-hour cumulative fecal pellet 
output was measured for each guinea pig.
       
Drugs and chemicals
The following drugs and chemicals were used: pentobarbital 
sodium (Hanlim Pharmaceuticals, Gyeonggi-do, Korea), iso-
tonic sodium chloride solution (Dai Han Pharmaceuticals, 
Seoul, Korea), charcoal (Sigma, Milwaukee, WI, USA), bar-
ium sulfate (Tae Joon Pharmaceuticals, Seoul, Korea), mo-
sapride (Dainippon Pharmaceuticals, Osaka, Japan), tegase-
rod maleate (Toronto Research Chemicals, North York, 
Canada), prucalopride (Janssen Pharmaceuticals, Beerse, 
Fig. 1. Radiologic images of postoperative ileus in a guinea pig model. The level of gas distention peaked at 3 hours after the operation (arrow).
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coal transit assay to investigate upper GI transit after stimu-
lation by various doses of mosapride, tegaserod, prucalo-
pride, or 5-HT. Following all drug treatments, upper GI 
transit was restored in a dose-dependent manner, increasing 
the ratio of charcoal migration to the total length of small 
intestine (Fig. 2).
The percentage of charcoal transit after administration of 
the highest dose (10 mg kg-1: n=8, 64.1±29.6%) of mo-
sapride was significantly increased compared to rates of tran-
sit after administration of vehicle (POI group: n=7, 0.7 
±1.3%, p<0.001) or the lowest dose of mosapride (1 mg kg-1: 
n=7, 12.4±11.1%, p<0.001) after Bonferroni analysis. The 
percentage of charcoal transit after administration of the 
highest dose of tegaserod (10 mg kg-1: n=5, 85.6±12.8%) 
was significantly higher than those after administration of 
vehicle (POI group: p<0.001) and the lowest dose of tegas-
erod (1 mg kg-1: n=5, 17.2±23.7%, p<0.001) after Bonfer-
roni analysis. The percentage of charcoal transit after ad-
ministration of the highest dose of prucalopride (10 mg kg-1: 
n=5, 83.5±11.3%) was significantly increased compared to 
those following administration of vehicle in the ‘POI’ group 
(p<0.001) and the lowest dose of prucalopride (0.5 mg kg-1: 
n=5, 2.7±3.2%, p<0.001) after Bonferroni analysis. The re-
sults of the charcoal transit assay in the prucalopride groups 
treated with 1 mg kg-1 (n=4, 67.7±18.7%, p<0.001) or 5 mg 
kg-1 (n=5, 78.9±20.7%, p<0.001) also showed significant 
differences compared with the vehicle-treated POI group. 
total small intestine length (cm) was 68.7±29.4% (n=7) and 
66.3±24.4% (n=5) in the ‘anesthesia’ and ‘sham operation’ 
groups, respectively (p>0.999). In the POI group, however, 
the charcoal migration length was 0.7±1.3% (n=7), which 
equates to almost no charcoal mixture moving into the small 
intestine. This difference was significant after post-hoc anal-
ysis of the upper GI transit results among the ‘POI’ group, 
‘anesthesia’ group, and ‘sham operation’ group (0.7% vs. 
68.7% vs. 66.3%, p<0.001) (Fig. 2).
The cumulative weights (g) of fecal pellets were signifi-
cantly different at all time points from 2 h to 5 h between the 
‘anesthesia’ and ‘POI’ groups (2.2 g vs. 0 g at 2 h, p=0.002; 
2.4 g vs. 0 g at 3 h, p=0.008; 2.8 g vs. 0 g at 4 h, p=0.002; 3.0 
g vs. 0.2 g at 4.5 h, p=0.003; 3.4 g vs. 0.5 g at 5 h, p=0.009). 
However, there was no significant difference in cumulative 
fecal pellet weight (g) between the ‘anesthesia’ and ‘POI’ 
groups at 1 h (1.3 g vs. 0 g at 1 h, p=0.075) (Fig. 3A). As 
shown in Fig. 3B, the cumulative numbers of fecal pellets 
showed significant differences between the ‘anesthesia’ and 
‘POI’ groups at all time-points from 1 h to 5 h. In short, up-
per GI motility was significantly delayed in the ‘POI’ group 
compared to both the ‘anesthesia’ and ‘sham operation’ 
groups, and lower GI motility was also significantly ham-
pered in the ‘POI’ group compared to the ‘anesthesia’ group.
Effects of 5-HT4 agonists on upper GI transit
The first series of dose-response experiments used the char-
Fig. 2. Results of the charcoal transit assay with various doses of mosapride, tegaserod, prucalopride, and 5-HT compared to postoperative ileus (POI), an-
esthesia, and sham operation groups. *Significant p value in prucalopride (10 mg/kg) group compared to POI and prucalopride (0.5 mg/kg) groups after 
Bonferroni analysis. †Significant p value in mosapride (10 mg/kg) group compared to POI and mosapride (1 mg/kg) groups after Bonferroni analysis. 
‡Significant p value in anethesia and sham operation groups compared with POI group after Bonferroni analysis. ††Significant p value in tegasored (10 mg/
kg) group compared to POI and tegaserod (1 mg/kg) groups after Bonferroni analysis. 5-HT, 5-hydroxytryptamine.
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‘sham operation’ group.
Effects of 5-HT4 agonists on lower GI transit
The second series of experiments was carried out to exam-
ine fecal pellet output after treatment with various doses of 
mosapride, tegaserod, prucalopride, or 5-HT. In vehicle-
treated (10 mg kg-1) guinea pigs of the POI group, the mean 
cumulative amount of excreted fecal pellets for 5 hours was 
0.5 g (n=6) (Fig. 3A). Following treatment with the highest 
dose (10 mg kg-1) of mosapride, tegaserod, or 5-HT, there 
was no significant increase in fecal pellet output (0.5 g, 0.4 
g, and 1.0 g, p>0.999 for all) compared to the vehicle-treat-
ed ‘POI’ group (0.5 g) (Figs. 4A, 5A, and 6A). Following 
treatment with prucalopride, however, delayed colonic mo-
In contrast, the results of charcoal transit after administra-
tion of various doses of 5-HT (1 mg kg-1: n=4, 1.8±0.8%, 
p>0.999; 5 mg kg-1: n=5, 6.2±5.9%, p>0.999; 10 mg kg-1: 
n=5, 32.0±10.7%, p=0.606) were not significantly different 
compared to those after administration of vehicle. At the 
highest doses tested, tegaserod and prucalopride achieved 
similar maximum prokinetic effects (equivalent to approxi-
mately 83-85% increases in charcoal transit). 
Interestingly, 1 mg kg-1 of prucalopride was as potent as 
10 mg kg-1 of mosapride or tegaserod by one-way ANOVA 
and Bonferroni test (p>0.999). Prucalopride, furthermore, 
showed considerable restoration of charcoal transit (67.7% 
at a dosage of 1 mg kg-1), a result equivalent to the 68.7% 
of that of the ‘anesthesia’ group and 66.3% of that of the 
Fig. 3. Results of fecal expulsion assay with the maximal doses (10 mg/kg-1) of each drug. (A) Cumulative fecal weights (g). (B) Cumulative numbers of fecal 
pellets. *Significant p value compared with POI group. POI, postoperative ileus; 5-HT, 5-hydroxytryptamine.
Fig. 4. The effects of mosapride on increasing cumulative fecal weight (g) and pellet number at each time-point, compared to the ‘anestheia’ and ‘POI’ 
groups.  (A) Cumulative fecal weights (g). (B) Cumulative numbers of fecal pellets. *Significant p value compared with the same time-point in the ‘POI’ group. 
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Fig. 5. The effects of tegaserod on increasing cumulative fecal weight (g) and pellet number at each time-point, compared to the ‘anestheia’ and ‘POI’ 
groups. (A) Cumulative fecal weights (g). (B) Cumulative numbers of fecal pellets. *Significant p value compared with the same time-point in the ‘POI’ group. 
POI, postoperative ileus.
Fig. 6. The effects of 5-HT on increasing cumulative fecal weight (g) and pellet number at each time-point, compared to the ‘anestheia’ and ‘POI’ groups. (A) 
Cumulative fecal weights (g). (B) Cumulative numbers of fecal pellets. *Significant p value compared with the same time-point in the ‘POI’ group. POI, post-
operative ileus; 5-HT, 5-hydroxytryptamine. 
Fig. 7. The effects of prucalopride on increasing cumulative fecal weight (g) and pellet number at each time-point, compared to the ‘anestheia’ and ‘POI’ 
groups. (A) Cumulative fecal weights (g). (B) Cumulative numbers of fecal pellets. *Significant p value compared with the same time-point in the ‘POI’ group. 
POI, postoperative ileus. 
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dog8 and rat.9 In contrast to these published data, one previ-
ous study in a ‘POI’ animal model showed that prucalopride 
only tended to increase colonic motility, and its effect was 
not clearly dose related. Only the lower dose (1 mg kg-1) of 
the drug significantly increased transit in the ‘sham opera-
tion’ group but not in the ‘POI’ group.5 This data is different 
from our results showing that prucalopride is the most ef-
fective 5-HT4 agonist to accelerate GI transit and increases 
both the weight and number of fecal pellets at the maximal 
dose (10 mg kg-1) in the ‘POI’ group. This discrepancy may 
be explained by the differences in the methods used and 
species employed in the POI model. In the contradicting 
study, prucalopride was injected intravenously into fasted 
rats 1 minute before the operation, and they were sacrificed 
20 minutes after intragastric administration of 0.1 mL Ev-
ans blue.5 Intestinal transit was measured as the migration 
of Evans blue from the pylorus to the most distal point of 
migration. Our methods are applicable to a clinical situation 
because the experiments were performed at the time of the 
worst stage of POI in guinea pig (3 hours after operation) 
and various 5-HT4 receptor agonists are commercially avail-
able as oral drugs. Although the opposing study used a dif-
ferent species, the 20-minute time point used may have 
been too early to compare the effects of the drugs. Further-
more, our fecal expulsion assay may be a more physiologic 
test for the comparison of the recovery of hampered colonic 
motility.
As POI represents a clinical indication for which there 
have been few approved therapies worldwide, vigorous 
studies are in progress to develop new drugs that inhibit 
neuroinflammatory or pharmacologic mechanisms. In POI, 
a local inflammatory process triggered by handling of the in-
testine activates inhibitory neural pathways and possibly 
triggers inflammation at distant untouched areas, leading to 
a generalized impairment of gastrointestinal motility.4 Thus, 
the use of prokinetic therapy to overcome an inhibitory neu-
ral pathway may lessen the severity of POI; however, the 
therapeutic efficacies of agents that stimulate propulsive pat-
terns of GI motility have been disappointing. Although the 
reason for the lack of efficacy of prokinetics for the treat-
ment of POI is unknown, it may relate to the fact that, in 
clinical trials, the compounds that have been studied have 
greater effects in promoting upper GI transit rather than 
stimulating colonic transit. That is, if a drug has effects on 
the stomach and the small intestine but not on the colon, 
such a drug would not be a successful treatment for POI in 
the clinic. Thus, the strategy for development of novel thera-
tility was reversed, resulting in an increase in excreted fecal 
weight compared to the vehicle-treated ‘POI’ group (3.0 g 
vs. 0.5 g, p=0.035) (Fig. 7A). In prucalopride-treated guin-
ea pigs, the mean cumulative amount of excreted fecal pel-
lets for the 5 hours following treatment were 2.2 g at the 
dose of 0.5 mg kg-1, 2.1 g at 1 mg kg-1, 2.8 g at 5 mg kg-1, and 
3.0 g at 10 mg kg-1. Only prucalopride significantly increased 
the amount of fecal pellet expelled (g) at the dose of 10 mg 
kg-1 (3.0 g vs. 0.5 g, p=0.035). There were no statistically 
significant differences in the doses of prucalopride lower 
than 10 mg kg-1.
The average cumulative number of fecal pellets expelled 
during the 5 hours after treatment was 25.2 in the ‘anesthe-
sia’ group (n=6). In contrast, in the vehicle-treated (10 mg 
kg-1) ‘POI’ guinea pigs, the average number of pellets was 
5.0 (n=4). In the groups treated with the highest doses of 
mosapride, tegaserod, or 5-HT (10 mg kg-1), the average 
numbers of pellets generated were 6.2 (n=5), 5.0 (n=5), and 
9.0 (n=4), respectively (Figs. 4B, 5B, and 6B). None of 
these values were significantly different from that of the ve-
hicle-treated ‘POI’ guinea pigs, and no significant changes 
in pellet expulsion were found with any of the lower con-
centrations of these drugs. Furthermore, there were no sta-
tistically significant increments in the number of fecal ex-
pulsion in any doses of mosapride, tegaserod, or 5-HT, 
except for prucalopride at 4 h (17.8 vs. 0, p=0.026) and 4.5 
h (22.3 vs. 2.25, p=0.050) at a dose of 5 mg kg-1 compared 
to the vehicle-treated ‘POI’ group, respectively, and at 4.5 h 
(21.8 vs. 2.25, p=0.001) and 5 h (28.7 vs. 5.0, p=0.005) at the 
dose of 10 mg kg-1 compared to the vehicle-treated ‘POI’ 
group, respectively (Fig. 7B). Overall, only prucalopride 
significantly increased fecal pellet weight and number in 
our experiments.
DISCUSSION
In this study, we demonstrated that oral administration of 
5-HT4 receptor agonists (mosapride, tegaserod, and pruca-
lopride) and 5-HT restored the delayed upper GI transit in a 
dose-dependent manner in a POI model, as determined by 
charcoal transit assay. However, only prucalopride clearly 
reversed the impeded colonic motility in the POI model, 
based on fecal pellet output.
Our in vivo data on 5-HT4 receptor-mediated stimulation 
of colonic motility with prucalopride was in agreement with 
published in vitro data on guinea pig6,7 and in vivo data on 
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es between agonists have come into the spotlight. Based on 
tissue-related properties (e.g., differences in receptor bind-
ing, agonist-specific signal transduction pathways, receptor 
density, coupling efficiency influenced by splice variants, 
and receptor desensitization), 5-HT4 receptor agonists are 
able to express tissue selectivity.17 Although the complexity 
and incompleteness of the underlying mechanisms hinder a 
clear-cut interpretation, some data on tissue-specificity has 
been published. Prucalopride stimulates 5-HT4 receptors on 
canine colon, which affects a regional coordinated relax-
ation-contraction mechanism in vivo.8 It induces to increase 
the motility pattern in the proximal colon and decrease the 
pattern motility in the distal colon. As a result, it facilitates 
the propulsion of luminal contents. This finding was similar 
to our previous results regarding mosapride.22 In addition, 
prucalopride apparently provokes propulsive waves of con-
tractions, named colonic giant migrating contractions, start-
ing in the proximal colon and progressing all the way to the 
anus.8 In contrast, tegaserod does not induce giant migrat-
ing contractions in the canine colon.20 Further studies are 
warranted to identify the mechanism of prucalopride to in-
crease colonic transit.
In conclusion, the newer 5-HT4 receptor agonist, prucalo-
pride, has clear-cut beneficial effects in the POI guinea pig 
model. Although mosapride and tegaserod also showed 
beneficial effects for the treatment of delayed upper GI tran-
sit, they may be of limited use in the treatment of POI. Pru-
calopride administered orally restores lower GI transit as 
well as upper GI transit after operation in a conscious guin-
ea pig. This drug may serve as a useful candidate for exam-
ination in a clinical trial for POI.
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